Status:
TERMINATED
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Lead Sponsor:
Bhuvaneswari Ramaswamy
Collaborating Sponsors:
Pfizer
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Biological therapies, such as agatolimod, may stimulate the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as trastuzumab, can block tumor gr...
Detailed Description
OBJECTIVES: Primary * To evaluate the progression-free survival of patients with HER2-overexpressing locally advanced or metastatic breast cancer treated with trastuzumab (Herceptin®) and agatolimod...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed breast cancer
- Locally advanced or metastatic disease
- HER2-overexpressing tumor, defined as 3+ overexpression by IHC and/or HER2 amplified by FISH
- Non-measurable disease allowed
- Achieved partial response, complete response, or stable disease (i.e., no disease progression for ≥ 12 weeks) while on trastuzumab (Herceptin®) and chemotherapy, hormonal therapy alone, or trastuzumab alone
- Last dose of trastuzumab must have been administered within the past 16 weeks
- No unstable brain metastases
- Patients with brain metastases are eligible provided they have been stable for ≥ 1 month after surgery or radiotherapy/radiosurgery AND off corticosteroids and anticonvulsants for ≥ 4 weeks
- Hormone receptor status unspecified
- PATIENT CHARACTERISTICS:
- ECOG(Eastern Cooperative Oncology Group)performance status (PS) 0-2 (Karnofsky PS 70-100%)
- Absolute neutrophil count ≥ 1,500/mm³
- Hemoglobin \> 8 g/dL (transfusion/epoetin alfa allowed)
- Platelet count ≥ 100,000/mm³
- Total bilirubin \< 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if known liver metastases)
- Creatinine \< 2 mg/mL
- Ejection fraction ≥ 50% by echocardiogram or MUGA
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception before, during, and for ≥ 3 months after completion of study treatment
- No ongoing or active infection requiring oral or IV antibiotics
- No known autoimmune disorders or antibody-mediated disorders
- No known HIV positivity
- No known history of hepatitis B or C (active and/or previously treated)
- No other malignancies within the past 5 years except nonmelanoma skin cancer or cervical cancer in situ
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 12 weeks since prior chloroquine
- More than 4 weeks since prior growth factors
- More than 4 weeks since prior systemic corticosteroids
- More than 4 weeks since prior chemotherapy, radiotherapy, or monoclonal antibody therapy (except trastuzumab)
- No prior agatolimod sodium
- No prior allogeneic stem cell transplantation
- No prior continuous treatment with single-agent trastuzumab for \> 6 months
- No more than 3 prior chemotherapy regimens for metastatic breast cancer
- Any number of prior hormonal therapies allowed
- No other concurrent investigational agents or monoclonal antibodies
- No other concurrent anticancer agents or therapies
- Concurrent bisphosphonates for skeletal metastasis allowed
Exclusion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00824733
Start Date
February 1 2009
End Date
April 1 2014
Last Update
January 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210